Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This article was retracted on 23 October 2022

This article has been updated

Abstract

Metastasis remains a main cause of mortality from breast cancer and an unresolved issue. The purpose of this study is to investigate the role of miR-302a in the development of breast cancer metastasis mediated by CXCR4, a critical regulator of metastasis, and to identify miR-302a as an effective therapeutic agent for therapy and prevention of breast cancer metastasis. Our studies show that miR-302a expression levels were downregulated in metastatic breast cancer cells and tumor tissues. Additionally, the expression levels of miR-302a were inversely correlated with CXCR4 levels. More promisingly, miR-302a inhibited the invasion and metastasis of breast cancer cells in vitro and in vivo and reduced the expression of CXCR4. Our findings demonstrated that the repression of miR-302a levels contributes to breast cancer metastasis and restoration of miR-302a baseline expression inhibits the invasion and metastasis of breast cancer cells. These data suggest that miR-302a mimics are potential therapeutic agents for breast cancer metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Change history

Abbreviations

miRNA:

MicroRNA

CXCR4:

CXC chemokine receptor 4

RT-PCR:

Reverse transcription polymerase chain reaction

SDF-1:

Stromal cell-derived factor-1

VEGF:

Vascular endothelial growth factor

MMP:

Matrix metalloproteinase

References

  1. Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12(2):121–127

    Article  CAS  PubMed  Google Scholar 

  2. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56

    Article  CAS  PubMed  Google Scholar 

  3. Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP, Ben-Baruch A (2001) A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 167(8):4747–4757

    Article  CAS  PubMed  Google Scholar 

  4. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62(6):1832–1837

    CAS  PubMed  Google Scholar 

  5. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC (2004) Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6(5):459–469

    Article  CAS  PubMed  Google Scholar 

  6. Liang Z, Yoon Y, Votaw J, Goodman M, William L, Shim H (2005) Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 65:967–971

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H (2004) Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 64(12):4302–4308

    Article  CAS  PubMed  Google Scholar 

  8. Yoon Y, Liang Z, Zhang X, Choe M, Zhu A, Cho HT, Shin DM, Goodman MM, Chen ZG, Shim H (2007) CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 67(15):7518–7524

    Article  CAS  PubMed  Google Scholar 

  9. Gontero P, Banisadr S, Frea B, Brausi M (2004) Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol 46(3):296–311

    Article  CAS  PubMed  Google Scholar 

  10. Turner HE, Harris AL, Melmed S, Wass JA (2003) Angiogenesis in endocrine tumors. Endocr Rev 24(5):600–632

    Article  CAS  PubMed  Google Scholar 

  11. Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S, Shim H (2007) CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 359(3):716–722

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hao L, Zhang C, Qiu Y, Wang L, Luo Y, Jin M, Zhang Y, Guo TB, Matsushima K, Zhang Y (2007) Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett 253(1):34–42

    Article  CAS  PubMed  Google Scholar 

  13. Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. Cell 122(1):6–7

    Article  CAS  PubMed  Google Scholar 

  14. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297

    Article  CAS  PubMed  Google Scholar 

  15. Slack FJ, Weidhaas JB (2006) MicroRNAs as a potential magic bullet in cancer. Future Oncol 2(1):73–82

    Article  CAS  PubMed  Google Scholar 

  16. Jiang J, Lee EJ, Gusev Y, Schmittgen TD (2005) Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 33(17):5394–5403

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Stadler B, Ivanovska I, Mehta K, Song S, Nelson A, Tan Y, Mathieu J, Darby C, Blau CA, Ware C, Peters G, Miller DG, Shen L, Cleary MA, Ruohola-Baker H (2010) Characterization of microRNAs involved in embryonic stem cell states. Stem cells Dev 19(7):935–950

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Cai N, Wang YD, Zheng PS (2013) The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. RNA 19(1):85–95

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Koga C, Kobayashi S, Nagano H, Tomimaru Y, Hama N, Wada H, Kawamoto K, Eguchi H, Konno M, Ishii H, Umeshita K, Doki Y, Mori M (2014) Reprogramming Using microRNA-302 Improves Drug Sensitivity in Hepatocellular Carcinoma Cells. Ann Surg Oncol.

  20. Liang Z, Ahn J, Guo D, Votaw JR, Shim H (2013) MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res 30(4):1008–1016

    Article  CAS  PubMed  Google Scholar 

  21. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, Scala S, Shim H (2010) Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79(6):817–824

    Article  CAS  PubMed  Google Scholar 

  22. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408

    Article  CAS  PubMed  Google Scholar 

  23. Shim H, Lau SK, Devi S, Yoon Y, Cho HT, Liang Z (2006) Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun 346(1):252–258

    Article  CAS  PubMed  Google Scholar 

  24. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9):643–655

    Article  CAS  PubMed  Google Scholar 

  25. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163):682–688

    Article  CAS  PubMed  Google Scholar 

  26. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12(3):247–256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD (2004) CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64(23):8604–8612

    Article  CAS  PubMed  Google Scholar 

  28. Fareh M, Turchi L, Virolle V, Debruyne D, Almairac F, de-la-Forest Divonne S, Paquis P, Preynat-Seauve O, Krause KH, Chneiweiss H, Virolle T (2012) The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ 19(2):232–244

    Article  CAS  PubMed  Google Scholar 

  29. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ (2006) miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34(Database issue):D140–D144

    Article  CAS  PubMed  Google Scholar 

  30. Cruz-Rivera E, Paul VJ (2007) Chemical deterrence of a cyanobacterial metabolite against generalized and specialized grazers. J Chem Ecol 33(1):213–217

    Article  CAS  PubMed  Google Scholar 

  31. Lipchina I, Studer L, Betel D (2012) The expanding role of miR-302-367 in pluripotency and reprogramming. Cell Cycle 11(8):1517–1523

    Article  CAS  PubMed  Google Scholar 

  32. Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DT, Chen DT, Ying SY (2008) Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 14(10):2115–2124

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Stenvang J, Silahtaroglu AN, Lindow M, Elmen J, Kauppinen S (2008) The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol 18(2):89–102

    Article  CAS  PubMed  Google Scholar 

  34. Love TM, Moffett HF, Novina CD (2008) Not miR-ly small RNAs: big potential for microRNAs in therapy. J Allergy Clin Immunol 121(2):309–319

    Article  CAS  PubMed  Google Scholar 

  35. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA (2007) Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67(6):2456–2468

    Article  CAS  PubMed  Google Scholar 

  36. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834–838

    Article  CAS  PubMed  Google Scholar 

  37. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39(5):673–677

    Article  CAS  PubMed  Google Scholar 

  38. Doench JG, Sharp PA (2004) Specificity of microRNA target selection in translational repression. Genes Dev 18(5):504–511

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1):15–20

    Article  CAS  PubMed  Google Scholar 

  40. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92–105

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Barroso-del Jesus A, Lucena-Aguilar G, Menendez P (2009) The miR-302-367 cluster as a potential stemness regulator in ESCs. Cell Cycle 8(3):394–398

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was financially supported by the Department of Defense Breast Cancer Program Concept Award (BC052118) to ZL as well as a Research Grant from NIH NCI (1R01CA165306) to HS. The authors thank Jessica Paulishen for proof-reading.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, 30322, USA

    Zhongxing Liang, Xuehai Bian & Hyunsuk Shim

  2. Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA

    Zhongxing Liang & Hyunsuk Shim

  3. Department of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Changchun, China

    Xuehai Bian

Authors
  1. Zhongxing Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuehai Bian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hyunsuk Shim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhongxing Liang or Hyunsuk Shim.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liang, Z., Bian, X. & Shim, H. RETRACTED ARTICLE: Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression. Breast Cancer Res Treat 146, 535–542 (2014). https://doi.org/10.1007/s10549-014-3053-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-014-3053-0

Keywords

Search

Navigation